• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Thursday, October 2, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Scientists are developing a way to counter ulcerative colitis

Bioengineer by Bioengineer
October 28, 2019
in Health
Reading Time: 2 mins read
0
IMAGE
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

KBFU center for clinical research scientists have participated in the international VARSITY clinical research

IMAGE

Credit: Immanuel Kant Baltic Federal University

Scientists from 34 countries with an IKBFU researcher among them are working on a medicine for the treatment of ulcerative colitis.

IKBFU center for clinical research scientists have participated in the international VARSITY clinical research. It’s the world’s first research aimed at finding the most effective drug among anti-inflammatory ones for the treatment of ulcerative colitis. Ulcerative colitis (UC) is a long-term condition that results in inflammation and ulcers of the colon and rectum. The disease can cause severe complications, starting with fistula in neighboring internal organs with a risk of peritonitis and ending with malignant neoplasms. The research was carried out in 245 research centers of 34 countries (19 Russian centers were among them). There were 771 patients aged from 18 to 85 years, with moderate and severe forms of ulcerative colitis.

Prof. Vladimir Rafalskiy, director of the IKBFU center for clinical research said: 15 years ago our opportunities in treating ulcerative colitis were quite limited. Doctors only had to use hormones glucocorticoids, the drug azathioprine, and salicylic acid derivatives. There were only three groups of drugs and the effectiveness of those groups was far from what was expected by doctors and patients alike. But the pharmacological science moves on and about ten years ago a new type of drugs was created. This is an innovative bio-genetic drug, producing antibodies blocking inflammation molecules and allowing very effective control of ulcerative colitis”.

Today’s pharmaceutical market offers patients with ulcerative colitis five drugs from the group of inhibitors of tumor necrosis factor and one anti-integrin drug. These are effective in treating the disease, especially in comparison with earlier drugs. Interestingly, the new generation drugs have never been compared.

Prof. Rafalskiy said:

“This is the first time when two new drugs are being compared. One of the drugs is an inhibitor of tumor necrosis factor and the other is an anti-integrin drug. The research was conducted from 2015 to 2019. The patients were randomly divided into two groups with different drugs (adalimumab and vedolizumab )administered to each group. There were several criteria for the research: clinical efficacy, the manifestation of the symptoms of the disease (participants filled in electronic diaries indicating the frequency of defecation, bleeding, abdominal pain, etc.), the results of colonoscopy before and after therapy, the results of histological examination, etc. The research has shown that vedolizumab is 9-12% more effective. And this difference is important for the treatment of ulcerative colitis. ”

###

The results were published in the medical journal “The New England Journal of Medicine“. Researchers from Icahn School of Medicine at Mount Sinai (New York, USA), Nancy University Hospital (Nancy, France), Mayo Clinic College of Medicine (Minnesota, USA), Ankara University School of Medicine (Ankara, Turkey), Takeda Development Center Europe (London, UK), University Hospital Schleswig-Holstein (Kiel, Germany).

Media Contact
Sergey Bulanov
[email protected]
7-921-268-5362

Original Source

http://eng.kantiana.ru/news/260770/

Related Journal Article

http://dx.doi.org/10.1056/NEJMoa1905725

Tags: Critical Care/Emergency MedicineGastroenterologyInfectious/Emerging DiseasesMedicine/Health
Share12Tweet8Share2ShareShareShare2

Related Posts

Comparing Methods to Measure Aggregate PFAS Exposure

October 2, 2025

Spin Squeezing Achieved in Diamond NV Centers

October 2, 2025

Spirituality Eases Occupational Stress in Nurses’ Lives

October 2, 2025

Hashimoto’s Thyroiditis: CA 19-9 and CA 72-4 Levels

October 2, 2025
Please login to join discussion

POPULAR NEWS

  • New Study Reveals the Science Behind Exercise and Weight Loss

    New Study Reveals the Science Behind Exercise and Weight Loss

    91 shares
    Share 36 Tweet 23
  • Physicists Develop Visible Time Crystal for the First Time

    74 shares
    Share 30 Tweet 19
  • New Study Indicates Children’s Risk of Long COVID Could Double Following a Second Infection – The Lancet Infectious Diseases

    73 shares
    Share 29 Tweet 18
  • How Donor Human Milk Storage Impacts Gut Health in Preemies

    64 shares
    Share 26 Tweet 16

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Validating Urban Flood Models with Multisource Data

Comparing Methods to Measure Aggregate PFAS Exposure

Spin Squeezing Achieved in Diamond NV Centers

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 60 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.